Molecular Partners (MOLN)

Executive Summary

Molecular Partners AG is a Swiss clinical-stage biotech leveraging its proprietary DARPin platform to develop multi-specific, logic-gated biologics for cancer, with a strategic pivot toward radiopharmaceuticals and immune cell engagers. The company's lead radiopharma asset, [212Pb]Pb-MP0712, targets DLL3 and is in a Phase 1/2 trial for neuroendocrine carcinomas and small cell lung cancer, enrolling since early 2026. Another key program, MP0533, is a trispecific CD3 engager targeting CD33, CD123, and CD70 in acute myeloid leukemia, currently in Phase 1/2 with combination arms. Additionally, MP0317 (FAP x CD40) is being evaluated in a Phase 2 trial for advanced biliary tract carcinoma in combination with chemotherapy and durvalumab. Despite past setbacks (e.g., terminated COVID-19 candidate ensovibep and several early-phase closures), the company maintains a focused pipeline and a cash position supporting operations into 2027 (est.). With a market cap of ~$153M, Molecular Partners offers a high-risk/high-reward opportunity in targeted oncology, with near-term catalysts expected from ongoing radiopharmaceutical and T-cell engager trials.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 initial data for [212Pb]Pb-MP0712 in DLL3-expressing tumors45% success
• H1 2027Phase 1/2 interim results for MP0533 combination therapy in AML50% success
• H2 2026Phase 2 enrollment completion and early efficacy data for MP0317 in biliary tract cancer55% success